229 related articles for article (PubMed ID: 30610008)
21. Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases.
Kim HS; Shaib WL; Zhang C; Nagaraju GP; Wu C; Alese OB; Chen Z; Brutcher E; Renfroe M; El-Rayes BF
Cancer; 2018 May; 124(9):1992-2000. PubMed ID: 29451701
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic sequences in patients with grade 1-2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group.
Faggiano A; Di Maio S; Mocerino C; Ottaviano M; De Divitiis C; Guarnotta V; Dolce P; Modica R; Puliafito I; Tozzi L; Di Sarno A; Leo S; Riccardi F; Palmieri G; Tafuto S; Bianco A; Badalamenti G; Colao A;
Endocrine; 2019 Nov; 66(2):417-424. PubMed ID: 30875056
[TBL] [Abstract][Full Text] [Related]
23. Advanced typical and atypical carcinoid tumours of the lung: management recommendations.
Melosky B
Curr Oncol; 2018 Jun; 25(Suppl 1):S86-S93. PubMed ID: 29910651
[TBL] [Abstract][Full Text] [Related]
24. Real-world treatment patterns in advanced pancreatic neuroendocrine tumors in the era of targeted therapy: perspectives from an academic tertiary center and community oncology practices.
Herring M; Huynh L; Duh MS; Vekeman F; Tiew A; Neary M; Bergsland E
Med Oncol; 2017 May; 34(5):88. PubMed ID: 28393314
[TBL] [Abstract][Full Text] [Related]
25. Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil.
Kaltsas GA; Mukherjee JJ; Isidori A; Kola B; Plowman PN; Monson JP; Grossman AB; Besser GM
Clin Endocrinol (Oxf); 2002 Aug; 57(2):169-83. PubMed ID: 12153595
[TBL] [Abstract][Full Text] [Related]
26. Analysis of Nonsurgical Treatment Options for Metastatic Rectal Cancer.
Wells SM; Boothe D; Ager BJ; Tao R; Gilcrease GW; Lloyd S
Clin Colorectal Cancer; 2020 Jun; 19(2):91-99.e1. PubMed ID: 32173281
[TBL] [Abstract][Full Text] [Related]
27. Sequencing of Somatostatin-Receptor-Based Therapies in Neuroendocrine Tumor Patients.
Strosberg JR; Al-Toubah T; El-Haddad G; Reidy Lagunes D; Bodei L
J Nucl Med; 2024 Mar; 65(3):340-348. PubMed ID: 38238038
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and Safety of
Zidan L; Iravani A; Oleinikov K; Ben-Haim S; Gross DJ; Meirovitz A; Maimon O; Akhurst T; Michael M; Hicks RJ; Grozinsky-Glasberg S; Kong G
J Nucl Med; 2022 Feb; 63(2):218-225. PubMed ID: 34049983
[TBL] [Abstract][Full Text] [Related]
29. Real-World Treatment Patterns for Lung Neuroendocrine Tumors: A Claims Database Analysis.
Broder MS; Cai B; Chang E; Neary MP; Papoyan E; Benson AB
Oncology; 2018; 94(5):281-288. PubMed ID: 29510379
[TBL] [Abstract][Full Text] [Related]
30. Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors.
Chong CR; Wirth LJ; Nishino M; Chen AB; Sholl LM; Kulke MH; McNamee CJ; Jänne PA; Johnson BE
Lung Cancer; 2014 Nov; 86(2):241-6. PubMed ID: 25218177
[TBL] [Abstract][Full Text] [Related]
31. Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices.
Velcheti V; Hu X; Piperdi B; Burke T
Sci Rep; 2021 Apr; 11(1):9222. PubMed ID: 33911121
[TBL] [Abstract][Full Text] [Related]
32. Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?
Mohamed A; Romano D; Saveanu A; Roche C; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Garcia S; Ferone D; Florio T; Moutardier V; Poizat F; Barlier A; Gerard C
Oncotarget; 2017 Jun; 8(25):41044-41063. PubMed ID: 28454119
[TBL] [Abstract][Full Text] [Related]
33. Does the dose matter? Antiproliferative efficacy and toxicity of everolimus in patients with neuroendocrine tumors - Experiences from a tertiary referral center.
Kiesewetter B; Melhorn P; Macheiner S; Wolff L; Kretschmer-Chott E; Haug A; Mazal P; Raderer M
J Neuroendocrinol; 2023 Aug; 35(8):e13319. PubMed ID: 37485760
[TBL] [Abstract][Full Text] [Related]
34. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience.
Gupta S; Yao JC; Ahrar K; Wallace MJ; Morello FA; Madoff DC; Murthy R; Hicks ME; Ajani JA
Cancer J; 2003; 9(4):261-7. PubMed ID: 12967136
[TBL] [Abstract][Full Text] [Related]
35. Treatment Outcomes in Patients with Metastatic Neuroendocrine Tumors: a Retrospective Analysis of a Community Oncology Database.
Fisher MD; Pulgar S; Kulke MH; Mirakhur B; Miller PJ; Walker MS; Schwartzberg LS
J Gastrointest Cancer; 2019 Dec; 50(4):816-823. PubMed ID: 30121904
[TBL] [Abstract][Full Text] [Related]
36. Real-world study of everolimus in advanced progressive neuroendocrine tumors.
Panzuto F; Rinzivillo M; Fazio N; de Braud F; Luppi G; Zatelli MC; Lugli F; Tomassetti P; Riccardi F; Nuzzo C; Brizzi MP; Faggiano A; Zaniboni A; Nobili E; Pastorelli D; Cascinu S; Merlano M; Chiara S; Antonuzzo L; Funaioli C; Spada F; Pusceddu S; Fontana A; Ambrosio MR; Cassano A; Campana D; Cartenì G; Appetecchia M; Berruti A; Colao A; Falconi M; Delle Fave G
Oncologist; 2014 Sep; 19(9):966-74. PubMed ID: 25117065
[TBL] [Abstract][Full Text] [Related]
37. In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy.
Syguła A; Ledwon A; Hasse-Lazar K; Jurecka-Lubieniecka B; Michalik B; Paliczka-Cieślik E; Zeman M; Chmielik E; Sczasny J; Jarzab B; Handkiewicz-Junak D
Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3841-3851. PubMed ID: 35503379
[TBL] [Abstract][Full Text] [Related]
38. Comparison of survival with somatostatin analog and chemotherapy and prognostic factors for treatment in 165 advanced neuroendocrine tumor patients with Ki-67 20% or less.
Özaslan E; Karaca H; Koca S; Sevinç A; Hacioğlu B; Özkan M; Özçelik M; Duran AO; Hacibekiroğlu İ; Yildiz Y; Tanriverdi Ö; Menekşe S; Aksoy A; Bozkurt O; Urvay S; Uysal M; Demir H; Çiltaş A; Dane F
Anticancer Drugs; 2017 Feb; 28(2):222-229. PubMed ID: 27768606
[TBL] [Abstract][Full Text] [Related]
39. Target therapies plus somatostatin analogs in NETs: a network meta-analysis.
Pusceddu S; Facciorusso A; Giacomelli L; Prinzi N; Corti F; Niger M; Milione M; Coppa J; Cascella T; Pulice I; Biamonte L; Papa S; Di Bartolomeo M; Shah A; Sacco R; de Braud F
Endocr Relat Cancer; 2021 Jun; 28(7):467-479. PubMed ID: 33979777
[TBL] [Abstract][Full Text] [Related]
40. Patient characteristics, treatment patterns, and clinical outcomes among patients with previously treated recurrent or metastatic cervical cancer: A community oncology-based analysis.
Alholm Z; Monk BJ; Ting J; Pulgar S; Boyd M; Sudharshan L; Bains S; Nicacio L; Coleman RL
Gynecol Oncol; 2021 May; 161(2):422-428. PubMed ID: 33741208
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
